ArticleNMR in biomedicine2026
Gradient Scheme Optimization for PRESS-Localized Edited MRS Using Weighted Pathway Suppression.
Article in NMR in biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-time AI integration for MR to detect artifacts and guide pulse sequence adaptations.bioRxiv : the preprint server for biology · 2026Article
- Gradient Scheme Optimization for PRESS-Localized Edited MRS Using Weighted Pathway Suppression.NMR in biomedicine · 2026Article
Corrections and comments
- Update of
Authors and funding
12 authors.
Funding
Abstract
This study aimed to design and implement an optimized gradient scheme for PRESS-localized edited magnetic resonance spectroscopy (MRS) to enhance suppression of out-of-voxel (OOV) artifacts. These artifacts, which originate from insufficient crushing of unwanted coherence transfer pathways (CTPs), are particularly challenging in editing schemes for metabolites like gamma-aminobutyric acid and glutathione. To address this, a volume-based likelihood model was developed to guide gradient scheme optimization, prioritizing suppression of CTPs based on likelihood. The volume-based likelihood model for CTP weighting was integrated into a Dephasing optimization through coherence order pathway selection (DOTCOPS) gradient optimization. Using a genetic algorithm with a weighted dual-penalty cost function, gradient schemes were optimized to maximize pathway-specific suppression. Hardware and sequence constraints, maximum gradient amplitudes and delay durations respectively, informed the optimization. Validation of the optimized scheme was performed with simulations by calculating the k-space crushing efficiency analytically with k-space trajectory and in vivo using an edited MRS sequence in three brain regions (posterior cingulate cortex PCC, thalamus, and medial prefrontal cortex [mPFC]), with particular focus on OOV artifact reduction and spectral quality improvements. A three-way Analysis of Variance was used to assess the significance level of OOV artifact reduction. The optimized gradient scheme demonstrated improved k-space crushing efficiency (by an average of 197%). OOV artifacts were reduced in all brain regions, particularly in highly OOV-susceptible regions (thalamus and mPFC). Improvements were most notable around 4.3 ppm with significant OOV artifact amplitude reductions (p < 0.001). By using a volume-based likelihood model for CTP prioritization, the optimized DOTCOPS scheme ensures robust and region-agnostic performance in reducing OOV artifacts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.